NCT06485466
- Conditions
- Apatinib, Camrelizumab, Transarterial Chemoembolization, +1 more
- Locations
-
- Sichuan Cancer Hospital and Research Institute Chengdu, Sichuan, China
Clinical trial condition
Transarterial Chemoembolization
Explore clinical trials studying Transarterial Chemoembolization. Study availability and eligibility vary by location and protocol.
16 public trials
6 recruiting studies
Transarterial Chemoembolization trial results
NCT06971991
- Conditions
- Radioembolization, Transarterial Chemoembolization, Transarterial Embolism
- Locations
-
- UW Hospital and Clinics Madison, Wisconsin, United States
NCT07417397
- Conditions
- Adenocarcinoma, Adjuvant, Carcinoma, +11 more
- Locations
-
- Guangxi Medical University Cancer Hospital Nanning, China
NCT07198230
- Conditions
- Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +15 more
- Locations
-
- The First Affiliated Hospital of Fujian Medical University Fuzhou, Fujian, China
NCT07178093
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Taichung Tzu-Chi Hospital Taichung, Taiwan
NCT06788353
- Conditions
- Systemic Therapy, Transarterial Chemoembolization, Unresectable Hepatocellular Carcinoma
- Locations
-
- The First Affiiated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China
Not Yet Recruiting
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
NCT07543510
- Conditions
- Adenocarcinoma, Atezolizumab Plus Bevacizumab, Carcinoma, +11 more
- Locations
-
Not specified
Not Yet Recruiting
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
NCT07281664
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
Not specified
NCT07562763
- Conditions
- Adenocarcinoma, Adjuvant Therapy, Carcinoma, +13 more
- Locations
-
- The First Affiliated Hospital of USTC Hefei, Anhu, China
Completed
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
NCT04834674
- Conditions
- Adenocarcinoma, Apatinib, Carcinoma, +7 more
- Locations
-
- Sichuan Cancer Hospital and Research Institute Chengdu, Sichuan, China